Answers are grounded in this paper and cite their sources.
Multicenter retrospective study shows sandwich strategy with TACE improves progression-free survival in hepatocellular carcinoma patients, highlighting treatment benefits.
Objective: This study aimed to evaluate the effect of sandwiching on-demand transcatheter arterial chemoembolization (TACE) during atezolizumab (Atezo) and bevacizumab (Bev) therapy on overall survival (OS) and progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (HCC). Methods: We retrospectively analyzed 398 patients who started Atezo/Bev therapy between October 2020 and April 2024. 245 patients were included: 51 in the ABC-TACE sandwich group and 194 in the Atezo/Bev alone group. Propensity score matching was performed to balance baseline characteristics, resulting in 49 matched patients per group. OS and PFS were analyzed using the Kaplan-Meier methods, with landmark analysis to adjust for immortal time bias. Multivariate analysis identified independent predictors of OS and PFS. Results: The ABC-TACE sandwich group had significantly longer OS (median, not reached vs. 21.0 months, p < 0.05) and PFS (18.7 months vs. 11.2 months, p < 0.05) than the Atezo/Bev alone group. Landmark analysis showed prolonged OS at multiple time points in the ABC-TACE sandwich group (p < 0.05, p < 0.05, p = 0.078). TACE independently contributed to both OS and PFS. No significant differences in adverse events were observed between the groups. No deterioration in the Child-Pugh score was observed before and after TACE (p = 0.976). Conclusion: Sandwiching TACE during Atezo/Bev therapy may improve survival outcomes for unresectable hepatocellular carcinoma.
No takes yet. Share an insight, caveat, or question.
Hashimoto et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: